Polycystic Kidney Disease – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of polycystic kidney disease (PKD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the prevalence and incidence of PKD for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s PKD forecast will answer the following question:

• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PKD over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

Clarivate Epidemiology forecasts 11 PKD patient populations:

• Diagnosed prevalent cases of autosomal dominant polycystic kidney disease (ADPKD).
• Diagnosed prevalent cases of definite ADPKD.
• Diagnosed prevalent cases of likely ADPKD.
• Diagnosed prevalent cases of mild ADPKD.
• Diagnosed prevalent cases of moderate ADPKD.
• Diagnosed prevalent cases of severe ADPKD.
• Diagnosed prevalent cases of low-risk rapid-progression ADPKD.
• Diagnosed prevalent cases of intermediate-risk rapid-progression ADPKD.
• Diagnosed prevalent cases of high-risk rapid-progression ADPKD.
• Diagnosed prevalent cases of autosomal recessive polycystic kidney disease (ARPKD).
• Diagnosed incident cases of ARPKD.

Note: Coverage may vary by country.